Pacira BioSciences, Inc.
PCRX
$26.30
$0.311.19%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -127.46M | -103.73M | -99.56M | -90.73M | 63.59M |
| Total Depreciation and Amortization | 89.99M | 81.53M | 78.79M | 76.03M | 74.21M |
| Total Amortization of Deferred Charges | 3.47M | 3.38M | 3.22M | 3.06M | 2.91M |
| Total Other Non-Cash Items | 227.75M | 219.97M | 225.46M | 225.32M | 73.77M |
| Change in Net Operating Assets | -59.22M | -25.41M | -18.52M | -9.83M | -20.12M |
| Cash from Operations | 134.52M | 175.75M | 189.39M | 203.84M | 194.36M |
| Capital Expenditure | -17.46M | -16.35M | -10.64M | -10.32M | -9.62M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -16.70M | -16.70M | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 18.16M | -60.33M | -72.64M | -64.22M | -17.10M |
| Cash from Investing | -16.00M | -93.38M | -83.28M | -74.53M | -26.71M |
| Total Debt Issued | 0.00 | 287.50M | 287.50M | 287.50M | 287.50M |
| Total Debt Repaid | -12.19M | -210.89M | -210.89M | -210.89M | -235.88M |
| Issuance of Common Stock | 2.50M | 2.30M | 2.30M | 2.50M | 2.53M |
| Repurchase of Common Stock | -55.61M | -25.67M | -25.49M | -25.52M | -25.49M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -36.06M | -36.06M | -36.06M | -36.06M |
| Cash from Financing | -65.30M | 17.19M | 17.36M | 17.54M | -7.40M |
| Foreign Exchange rate Adjustments | 204.00K | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 53.43M | 99.56M | 123.48M | 146.85M | 160.24M |